Literature DB >> 3698174

Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

F Y Lee, P Workman.   

Abstract

We have studied the effect of misonidazole (MISO) on the antitumour activity, normal tissue toxicity and pharmacokinetics of four bifunctional nitrogen mustards: chlorambucil (CHL); phenylacetic acid mustard (PAAM), a metabolite of CHL; beta, beta-difluorochlorambucil (beta-F2CHL), an analogue which is metabolized less efficiently by the beta-oxidation pathway; and melphalan (MEL). MISO (2.5 mmol/kg) increased the response of the KHT tumour to CHL, PAAM and beta-F2CHL by dose-modifying factors (DMFs) of 1.55-1.85, 1.35-1.65 and 1.5-1.8, respectively. In contrast, the activity of MEL was not altered. However, with 5.0 mmol/kg MISO an enhanced response to MEL was observed (DMF = 1.35-1.55). Similarly, for CHL and PAAM, but not MEL, acute toxicity was also increased by 2.5 mmol/kg MISO. The increase in toxicity with CHL and PAAM was similar to the increase in antitumour activity, and their therapeutic indices were unchanged. Effective chemosensitizers were shown to be powerful inhibitors of drug clearance. Thus, potent chemosensitizers such as MISO, the lipophilic analogue benznidazole (BENZO), the microsomal enzyme inhibitor SKF 525A, and the parent heterocycle imidazole all reduced the plasma clearance of CHL and its metabolites and therefore increased drug exposure (AUC). Conversely, the hydrophilic MISO metabolite Ro 05-9963 was a poor chemosensitizer and produced only very weak pharmacokinetic effects. As the DMFs for chemosensitization agreed very well with those for increased AUC, it seems likely that pharmacokinetic changes are the major cause of the enhancement of tumour response to CHL. For MEL, chemosensitization also appears to be related to pharmacokinetic changes. MISO at a dose of 2.5 mmol/kg produced no change in MEL pharmacokinetics and no enhancement of tumour response, whereas 5.0 mmol/kg MISO was effective on both counts.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698174     DOI: 10.1007/bf00299862

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

Review 1.  Modification of chemotherapy by nitroimidazoles.

Authors:  D W Siemann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

2.  The metabolism of chlorambucil.

Authors:  A McLean; D Newell; G Baker; T Connors
Journal:  Biochem Pharmacol       Date:  1980-07-15       Impact factor: 5.858

3.  Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.

Authors:  R D Clutterbuck; J L Millar; T J McElwain
Journal:  Am J Clin Oncol       Date:  1982-02       Impact factor: 2.339

Review 4.  The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles.

Authors:  J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

5.  Nitroimidazoles as modifiers of nitrosourea pharmacokinetics.

Authors:  F Y Lee; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

6.  Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.

Authors:  C N Coleman; M K Friedman; C Jacobs; J Halsey; R Ignoffo; S Leibel; V K Hirst; M Gribble; S K Carter; T L Phillips
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

7.  In vitro degradation of L-phenylalanine mustard (L-PAM).

Authors:  T L Evans; S Y Chang; D S Alberts; I G Sipes; K Brendel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

10.  Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

View more
  7 in total

1.  Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.

Authors:  María Elena Marson; Jaime Altcheh; Guillermo Moscatelli; Samanta Moroni; Facundo García-Bournissen; Guido Enrique Mastrantonio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 2.441

2.  Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Authors:  D J Stewart; R Goel; M C Cripps; S Huan; J Yau; S Verma
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.

Authors:  P K Quinn; M C Bibby; J A Cox; S M Crawford
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

6.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

7.  Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

Authors:  I J Stratford; G E Adams; J Godden; J Nolan; N Howells; N Timpson
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.